Premium
NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY
Author(s) -
Zinzani P. L.,
Santoro A.,
Gritti G.,
Brice P.,
Barr P. M.,
Kuruvilla J.,
Cunningham D.,
Kline J.,
Johnson N. A.,
MehtaShah N.,
Fanale M.,
Francis S.,
Moskowitz A. J.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.51_2879
Subject(s) - brentuximab vedotin , medicine , nivolumab , refractory (planetary science) , oncology , phases of clinical research , gastroenterology , lymphoma , surgery , cd30 , chemotherapy , cancer , immunotherapy , physics , astrobiology